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Abstract
Background: Associations of diet with dilated cardiomyopathy are under
investigation.
Objectives: That cardiac assessment would show abnormalities in healthy dogs eat-
ing grain-free (GF) diets or diets with Food and Drug Administration (FDA)-listed
ingredients of concern (peas, lentils, or potatoes) as top 10 ingredients (FDA-PLP),
but not in dogs eating grain-inclusive (GI) diets or diets without FDA-listed ingredi-
ents of concern (PLP) in the top 10 ingredients (NoFDA-PLP).
Animals: One hundred eighty-eight healthy Doberman Pinschers, Golden Retrievers,
Miniature Schnauzers, and Whippets.
Methods: This study was an observational cross-sectional study. Echocardiograms,
cardiac biomarkers, and blood and plasma taurine concentrations were compared
between dogs eating GF (n = 26) and GI (n = 162) diets, and between FDA-PLP
(n = 39) and NoFDA-PLP (n = 149) diets, controlling for age and breed. Demographic
characteristics, murmurs, genetic status, and ventricular premature complexes (VPCs)
during examination were compared between dogs eating different diet types.
Results: No differences in echocardiographic variables, N-terminal pro-B-type natri-
uretic peptide or whole blood taurine were noted between dogs eating different diet
types. Dogs eating GF diets had higher median high-sensitivity cardiac troponin I
(hs-cTnI) (GF 0.076 ng/mL [Interquartile range (IQR), 0.028-0.156] vs. GI 0.048 [IQR,
0.0026-0.080]; P < .001) and higher median plasma taurine (GF 125 nmol/mL [IQR,
101-148] vs GI 104 [IQR, 86-123]; P = .02) than dogs eating GI diets. Dogs eating
FDA-PLP diets had higher median hs-cTnI (0.059 ng/mL [IQR, 0.028-0.122]) than
dogs eating NoFDA-PLP diets (0.048 [IQR, 0.025-0.085]; P = .006). A greater
Abbreviations: EF, ejection fraction; FDA, Food and Drug Administration; FDA-PLP, diets with FDA-listed ingredients of concern (peas, lentils, potatoes) in the top 10 ingredients; FS, fractional
shortening; GF, grain free; GI, grain inclusive; hs-cTnI, high-sensitivity cardiac troponin I; LA/Ao, left atrial to aortic diameter; LV, left ventricular; LVIDdN, normalized left ventricular internal
diameter in diastole; LVIDsN, normalized left ventricular internal diameter in systole; LVVd/m2, left ventricular volume in diastole indexed to body surface area; LVVs/m2, left ventricular volume
in systole indexed to body surface area; nDCM, nutritional dilated cardiomyopathy; NoFDA-PLP, diets without FDA-listed ingredients of concern (peas, lentils, potatoes) in the top
10 ingredients; NT-proBNP, N-terminal pro B-type natiuretic peptide; PLP, peas, lentils, potatoes.
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proportion of dogs eating FDA-PLP diets (10%) had VPCs than dogs eating NoFDA-
PLP diets (2%; P = .04).
Conclusions and Clinical Importance: Higher hs-cTnI in healthy dogs eating GF and
FDA-PLP diets might indicate low-level cardiomyocyte injury.
K E YWORD S
dilated cardiomyopathy, food, grain free, grain inclusive, NT-proBNP, troponin
1 | INTRODUCTION
Dilated cardiomyopathy is a disease of dogs that is associated with
short duration of survival once clinical signs of congestive heart failure
are detected.1,2 The disease has genetic causes in several large and
giant breeds and is uncommon in small breed dogs.1,3-5 The increased
recognition of dilated cardiomyopathy in atypical breeds in recent
years, coupled with the observation of dietary commonalities in these
dogs, prompted clinical publications and increased reporting of affected
cases to the Food and Drug Administration (FDA).6-8 Reports describing
dogs suspected to have a nutritional basis for this cardiac condition,
and recovery of some dogs after nutritional intervention are currently
limited to a small retrospective study6 and 2 prospective studies.7,8 Die-
tary characteristics possibly associated with nutritional dilated cardio-
myopathy (nDCM) include the absence of grains and inclusion of peas,
lentils, or potatoes as main ingredients. The accurate classification and
description of diets implicated in nDCM has been elusive.
Theoretical reasons for dog foods that are grain free (GF) or high
in peas, lentils, or potatoes to be associated with nDCM include nutri-
tional deficiencies, poor nutrient bioavailability, impaired taurine
metabolism or precursor availability, nutrient-to-nutrient interactions,
or presence of toxic substances.9 Genetic makeup or other modifying
factors could also influence disease expression in some dogs and
explain why not all dogs eating these diets are affected. Alternatively,
it remains possible that this apparent association is confounded by
other factors.10 Although some affected dogs are taurine deficient
(especially Golden Retrievers7), thereby strengthening the association
with food, the majority of dogs with suspected nDCM have normal
blood taurine concentrations.6 The role of taurine is uncertain at this
time.11-14
Nutritional dilated cardiomyopathy is a complex disorder with
uncertain etiologies, undetermined contribution of dietary factors,
variable phenotype, and unclear extradietary modifiers of disease
expression. Many diseases have a spectrum of severity ranging from
mild to overt disease, and so it is possible that some healthy dogs
have subclinical cardiac abnormalities related to diet type. One study
reported echocardiograms from clinically healthy Golden Retrievers,8
but additional studies evaluating for subclinical disease related to diet
are needed to facilitate efforts at early intervention and to enhance
understanding of the natural history and pathophysiology of nDCM.
The purpose of this observational study was to evaluate the effect of
diet type on blood and plasma taurine concentrations, cardiac bio-
markers, and echocardiograms in apparently healthy dogs of 4 breeds.
We hypothesized that echocardiographic chamber dimensions and
cardiac biomarkers would be higher in dogs eating diets that are GF or
high in peas, lentils, or potatoes, compared with dogs eating diets
without these characteristics, and that taurine concentrations would
not differ between dogs eating diets with and without these
characteristics.
2 | METHODS
This study was an observational cross-sectional study that was
approved by the Institutional Animal Care and Use Committees at the
University of Florida, College of Veterinary Medicine (#201810504)
and the University of Wisconsin, School of Veterinary Medicine
(#V005029-R01). All dog owners provided informed consent. Dogs
were recruited for study enrollment at the University of Florida and
the 2019 American Whippet Club National Specialty breed show in
Topeka, Kansas. Dogs were recruited and enrolled irrespective of age,
sex, or diet type.
2.1 | Inclusion criteria
Dogs were included if they were considered to be clinically healthy,
had been eating a commercial dog food for at least 6 months, and
were a purebred Whippet, Golden Retriever, Doberman Pinscher, or
Miniature Schnauzer. We specifically selected 2 breeds with no
known genetic predisposition to dilated cardiomyopathy (Miniature
Schnauzer and Whippet), 1 with known heritable dilated cardiomyop-
athy (Doberman Pinscher), and 1 that appears to be at increased risk
for nDCM (Golden Retriever), although appropriate epidemiological
data for this condition are lacking. Four breeds with notably different
characteristics were chosen for this study to test the hypotheses in
diverse breeds without introducing extensive breed variability. The
study was not designed to evaluate each breed individually.
2.2 | Exclusion criteria
Dogs were not included if they were fed more than 1 type of food
within the 6 months before presentation, were receiving taurine sup-
plementation, were receiving cardiac medications, or had known car-
diac disease. Dogs with clinically important extracardiac diseases were
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excluded, as were female dogs that were pregnant, lactating, or in
estrous.
2.3 | Procedures
2.3.1 | Examination and diet history
Body weight, body condition score (1-9 scale),15 muscle condition
score (normal, mild, moderate, or severe muscle loss),16 and results
of a physical examination were recorded for all dogs. Owners filled
out a diet history form detailing specific foods, treats, supplements,
and the duration of feeding. Biotin containing supplements were
specifically noted because of the potential for mega-doses of this vita-
min to interfere with high-sensitivity cardiac troponin I (hs-cTnI)
measurement.17,18
2.3.2 | Categorization of diets
The ingredient list of the diets fed to enrolled dogs were reviewed for
categorization based on the presence of grains and separate categori-
zation based on whether peas, lentils, or potatoes were listed in the
top 10 ingredients based on the FDA's advisory (https://www.fda.
gov/animal-veterinary/outbreaks-and-advisories/fda-investigation-
potential-link-between-certain-diets-and-canine-dilated-
cardiomyopathy). Diets were categorized as GF if there were no
grain-containing or grain-derived ingredients listed and as grain inclu-
sive (GI) if grain-containing or grain-derived ingredients were listed.
Grain-containing or grain-derived ingredients included whole-grain
products or refined-grain products made from any part of wheat, rice,
oats, corn, barley, or another cereal grain.19 Oils were not considered
a grain product. Diets were separately categorized as having FDA-
listed ingredients of concern (peas, lentils, or potatoes) in the top 10
ingredients (FDA-PLP) or as without FDA-listed ingredients of con-
cern (peas, lentils, or potatoes) in the top 10 ingredients (NoFDA-
PLP). Inclusion of taurine and methionine as dietary ingredients was
noted because these amino acids could affect blood taurine
concentrations.20
2.3.3 | Echocardiography
A standard echocardiogram was performed without sedation and with
monitoring electrocardiography. Echocardiographic variables assessing
left ventricular (LV) size and function were measured offline after all
dogs were enrolled, with the investigators blinded to dog identity and
dietary history. Reported values are the average of triplicate measure-
ments. Two-dimensional volume indices were determined using a
4-chamber, right-sided long-axis view and the modified disk summa-
tion method.21 Left ventricular volumes in diastole and systole were
indexed to body surface area (LVVd/m2 and LVVs/m2, respectively).22
Ejection fraction (EF) was calculated as the percent change in LV
volume between diastole and systole. The right-sided short-axis view
at the level of the chordae tendineae was used for M-mode measure-
ments of LV size including LV internal dimension in diastole and sys-
tole normalized for body length using allometric scaling according to
2 formulas (normalized LV internal diameter in diastole [LVIDdN] and
normalized LV internal diameter in systole [LVIDsN], respec-
tively).23,24 Fractional shortening (FS) was calculated as the percent
change in LV diameter between diastole and systole using M-mode
measurements. Left atrium to aortic diameter ratio (LA/Ao) was deter-
mined in the right-sided short-axis parasternal view in mid-diastole
using 2D measurements.25 Rhythm during the echocardiogram was
noted.
2.3.4 | Genotyping
Doberman Pinschers were tested at the North Carolina State Univer-
sity Veterinary Genetics Laboratory (Raleigh, North Carolina) using a
buccal swab for genetic mutations (DCM1 and DCM2) associated
with dilated cardiomyopathy in this breed.3,4
2.3.5 | Blood sampling
Blood was collected by peripheral venipuncture into either 3-mL
tubes (Doberman Pinchers, Whippets, Golden Retrievers) or 1-mL
tubes (Miniature Schnauzers) for subsequent testing. Only non-
hemolyzed serum and plasma samples were used for testing. Lithium
heparinized whole blood and plasma samples were analyzed for whole
blood and plasma taurine concentrations by the Amino Acid Labora-
tory, University of California, Davis (Davis, California). Serum samples
were analyzed for hs-cTnI concentrations by the Gastrointestinal Lab-
oratory, Texas A & M University (College Station, Texas) using the
ADVIA Centaur Troponin I Ultra analyzer (Siemens Healthcare Diag-
nostics, Deerfield, Illinois) which has been validated for use in dogs.26
Ethylenediaminetetraacetic acid (EDTA) plasma samples were ana-
lyzed for N-terminal pro B-type natriuretic peptide (NT-proBNP) con-
centrations by IDEXX Laboratories (Westbrook, Maine). In-house
SNAP 4Dx test (IDEXX Laboratories, Westbrook, Maine) was per-
formed on EDTA plasma of dogs enrolled at the University of Florida
that had elevated hs-cTnI concentrations to screen for common infec-
tious diseases that could cause cardiac troponin I elevations.
2.4 | Statistical analysis
Commercial software was used for data analysis (SAS 9.4, Cary, North
Carolina). Data are presented as median and interquartile range (IQR).
Differences in the baseline characteristics of dogs in each diet type
group were compared using Fisher's exact test or chi-square test and
Mann-Whitney test for categorical and continuous variables, respec-
tively. Differences in selected echocardiographic variables (LVIDdN
and LVIDsN using both allometric formulas, LA/Ao, FS, LVVD/m2,
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LVVS/m2, EF), whole blood and plasma taurine concentrations,
hs-cTnI concentrations, and NT-proBNP concentrations were com-
pared between dogs eating GF and GI diets and between dogs eating
FDA-PLP and NoFDA-PLP diets using analysis of variance tests.
Crude, unadjusted analyses were performed to examine the associa-
tion between the different diet categorizations and our principal study
outcomes. We then performed multivariable regression analyses
examining these associations while controlling for the dogs' age and
breed, yielding multivariable adjusted P values.
The prevalence of murmurs, occurrence of arrhythmias noted on
monitoring electrocardiogram during echocardiography, and genetic
positivity for Doberman Pinschers (heterozygous or homozygous for
either mutation) were compared between dogs eating GF and GI diets,
and between dogs eating FDA-PLP and NoFDA-PLP diets using Fish-
er's exact test. Significance was set at P < .05.
3 | RESULTS
3.1 | Study population
A total of 188 dogs met the inclusion criteria and were enrolled in this
study. All enrolled Whippets (n = 86) were evaluated over a 3-day
period at the 2019 American Whippet Club National Specialty breed
show in Topeka, Kansas. Dogs from the other 3 breeds (37 Doberman
Pinschers, 43 Golden Retrievers, and 22 Miniature Schnauzers) were
enrolled at the University of Florida between May 2019 and July 2020.
There were no significant differences in terms of age, weight, sex,
or time eating the diet before enrollment according to the type of diet
consumed (Table 1). There were no differences in genetic status
between Doberman Pinschers fed GF and GI diets or between Dobe-
rman Pinschers fed FDA-PLP and NoFDA-PLP diets. No differences in
murmur prevalence were present between diet types. All murmurs
were low grade (1/6 or 2/6). The proportion of dogs with ventricular
premature complexes (VPCs) noted on the monitoring
electrocardiogram during echocardiography was significantly higher
for dogs eating FDA-PLP diets compared with NoFDA-PLP
diets (P = .04).
The majority (92%) of dogs in the study were assessed as has hav-
ing normal muscle condition. Muscle condition scores were not signifi-
cantly different between diet categorizations after controlling for age
and breed (median and IQR scores were normal for all groups;
adjusted P = .70 comparing GF to GI and adjusted P = .63 comparing
FDA-PLP to NoFDA-PLP). Median [IQR] body condition score was 5.0
[5.0-6.0] for dogs eating GF and FDA-PLP diets and 5.0 [5.0-5.0] for
dogs eating GI and NoFDA-PLP diets. Body condition scores were not
different between diet categorizations after controlling for age and
breed (adjusted P = .76 for GF compared to GI and adjusted P = 0.10
for FDA-PLP compared to NoFDA-PLP).
3.2 | Diets and supplements
The 188 dogs in this study were fed 72 diets, which were represented
by 34 different brands. All diets were dry kibble. Table 2 shows the
number of dogs from each breed that were eating each diet type.
3.2.1 | Categorization based on GI
There were 21 GF diets (15 different manufacturers) and 51 GI diets
(22 different manufacturers) (Table S1). The proportion of diets with
taurine or methionine included as ingredients was not statistically dif-
ferent between diet types (GF 16/21; 76%, GI 28/51; 55%, P = .12).
Twenty-six dogs were eating GF diets and 162 dogs were eating GI
diets. The proportion of dogs eating GF diets that included taurine or
methionine as ingredients (21/26; 81%) was greater than the propor-
tion of dogs eating GI diets that included taurine or methionine as
ingredients (63/162; 39%, P < .001).
TABLE 1 Demographic characteristics, genetic status, murmurs, and ventricular premature complexes in dogs based on diet characterization
GF (n = 26) GI (n = 162) P value FDA-PLP (n = 39) NoFDA-PLP (n = 149) P value
Age (months) 50 (36-99) 49 (30-79) .38 45 (24-87) 50 (30-81) .99
Weight (kg) 24.3 (9.1-32.9) 17.7 (14.2-29.6) .87 24.0 (13.4-32.0) 17.7 (14.2-29.4) .75
Months on diet before presentation 20 (15-48) 24 (12-40) .48 21 (15-47) 24 (11-40) .37
Male 10 (39%) 61 (38%) 1.0 11 (28%) 60 (40%) .20
Positive genetic status DP (n = 37) 5 (71%) 18 (60%) .69 5 (56%) 18 (64%) .70
Murmur 6 (23%) 46 (28%) .70 11 (28%) 41 (28%) .65
VPCs during echocardiogram (# of each breed) 3 (12%)
(2 DP, 1 GR)
4 (3%)
(3 DP, 1 GR)
.06 4 (10%)




Note: Median and interquartile range are shown for the first 3 variables. Number and percentage of the total are shown for the remaining variables.
Genetic status was considered positive if Doberman Pinschers were heterozygous or homozygous for either the DCM1 or DCM2 mutations. P < .05 was
considered significant (bolded).
Abbreviations: DP, Doberman Pinschers; FDA-PLP, diets with Food and Drug Administration ingredients of concern (peas, lentils, or potatoes) in the top
10 ingredients; GF, grain-free diets; GI, grain-inclusive diets; GR, Golden Retrievers; NoFDA-PLP, diets without Food and Drug Administration ingredients
of concern (peas, lentils, or potatoes) in the top 10 ingredients; VPCs, ventricular premature complexes.
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3.2.2 | Categorization based on FDA ingredients of
concern in top 10 ingredients
There were 29 FDA-PLP diets (21 different manufacturers) and
43 NoFDA-PLP diets (19 different manufacturers) (Table S2). The pro-
portion of diets with taurine or methionine included as ingredients
was not statistically different between diet types (FDA-PLP 22/29;
76%, NoFDA-PLP 22/43; 51%, P = 0.05). Thirty-nine dogs were eat-
ing FDA-PLP diets and 149 dogs were eating NoFDA-PLP diets. The
proportion of dogs eating FDA-PLP diets that included taurine or
methionine as ingredients (29/39; 74%) was greater than the propor-
tion of dogs eating NoFDA-PLP diets that included taurine or methio-
nine as ingredients (55/149; 37%, P < .001).
3.2.3 | Biotin supplementation
A minority (3.2%; 6/188) of dogs were receiving biotin supplementa-
tion as a component of a multivitamin fed separate from their main
diet. The proportion of dogs eating GF diets that received biotin sup-
plementation (1/26; 3.8%) was not different from the proportion of
dogs eating GI diets that received biotin supplementation (5/162;
3.1%, P = 1.0). Findings were similar for dogs eating FDA-PLP diets
(1/39; 2.5% received biotin supplementation) and NoFDA-PLP diets
(5/149; 3.4% received biotin supplementation; P = 1.0).
3.3 | Echocardiography, cardiac biomarkers, and
taurine concentrations
After multivariable regression, no differences were found between
diet categorizations (GF vs GI and FDA-PLP vs NoFDA-PLP) for any
echocardiographic variables, NT-proBNP, or whole blood taurine con-
centrations (Table 3). Median hs-cTnI (P < .001) and median plasma
taurine concentrations (P = .02) were both significantly higher in dogs
eating GF diets compared to GI diets and median hs-cTnI concentra-
tion (P = .006) was significantly higher in dogs eating FDA-PLP diets
compared to NoFDA-PLP diets (Table 3).
3.4 | SNAP 4Dx
Twenty-eight dogs enrolled at the University of Florida showed ele-
vated serum hs-cTnI concentrations and so underwent in-house SNAP
4Dx testing. All dogs were negative for Dirofilaria immitis antigen,
Anaplasma phagocytophilum antibody, Anaplasma platys antibody,
Ehrilichia canis antibody, and Ehrlichia ewingii antibody. One dog was
determined to be positive for Borrelia burgdoferi C6 antibody. This dog
was eating a diet categorized as GI and NoFDA-PLP.
4 | DISCUSSION
This study of 4 dog breeds found significantly higher hs-cTnI concen-
trations in healthy dogs eating GF diets compared to dogs eating GI
diets, and in healthy dogs eating FDA-PLP diets compared to dogs
eating NoFDA-PLP diets, and these differences persisted after con-
trolling for the dogs' age and breed. Serum concentrations of cardiac
troponin I are low in healthy dogs.27 Myocardial cell injury is associ-
ated with release of troponin I into the circulation, allowing for its
detection by analyzers.27,28 Low-level increases in serum cardiac tro-
ponin I concentrations occur in many cardiac diseases including in
people with unhealthy dietary profiles.27,29,30 Although biotin supple-
mentation (but not dietary biotin) can interfere with hs-cTnI by many
analyzers,17,18 this possible concern most likely did not influence
the current results because only a small minority of dogs received
biotin-containing dietary supplements, with equal proportions of dogs
between diet types. The importance of low-level increases in serum
cardiac troponin I are not always clear, but in people are associated
with both exercise and subclinical cardiac injury.29-31 The hs-cTnI has
prognostic value in dogs with degenerative mitral valve disease, with
concentrations above a relatively low cutoff of .025 ng/mL associated
with decreased survival.32 In addition, low-level cardiac troponin T
concentrations induced in rats by monosodium glutamate administra-
tion correlates with other blood markers of cardiac injury and histo-
logic evidence of cardiac myofiber swelling and degeneration.33 The
reasons for the higher hs-cTnI concentrations in dogs eating GF and
FDA-PLP diets could not be determined from this study, but this find-
ing provides basic mechanistic information to guide future studies of
the etiology of nDCM.
Dogs eating GF diets as a group also had higher plasma, but not
whole blood taurine concentrations compared to dogs eating GI diets.
Differences in blood or plasma taurine concentrations were not found
for dogs eating FDA-PLP and NoFDA-PLP diets. The higher plasma
taurine concentration in dogs eating GF diets compared to dogs eat-
ing GI diets could be a result of the inclusion of taurine or methionine
as ingredients in the diets eaten by more dogs in the GF group
TABLE 2 Breed distribution for each
diet type classification
GF (n = 26) GI (n = 162) FDA-PLP (n = 39) NoFDA-PLP (n = 149)
Doberman Pinscher 7 30 9 28
Golden Retriever 8 35 12 31
Miniature Schnauzer 8 14 8 14
Whippet 3 83 10 76
Abbreviations: FDA-PLP, diets with Food and Drug Administration ingredients of concern (peas, lentils,
or potatoes) in the top 10 ingredients; GF, grain-free diets; GI, grain-inclusive diets; NoFDA-PLP, diets
without Food and Drug Administration ingredients of concern (peas, lentils, or potatoes) in the top 10
ingredients.
ADIN ET AL. 775
compared to the GI group. Oral supplementation with taurine and die-
tary inclusion of taurine and methionine increase plasma taurine con-
centrations independent of whole blood taurine concentrations34,35
but 1 study showed both higher whole blood and plasma taurine con-
centrations in dogs eating diets fortified with taurine and methio-
nine.20 Alternatively, the higher plasma taurine concentrations in dogs
eating GF diets might be caused by cardiomyocyte injury, which could
be supported by the finding that hs-cTnI was also higher in dogs eat-
ing GF diets compared to GI diets. Circulating taurine concentrations
have historically been used as a biomarker of myocardial injury in peo-
ple, although whole blood concentrations seem more closely associ-
ated with injury than plasma concentrations in some studies.36-38
Elevated plasma taurine concentrations in conjunction with low
intramyocardial taurine concentrations in a rat model of
isoproterenol-induced myocardial injury resulted from defective myo-
cardial taurine transport and increased sarcolemmal taurine release
associated with cardiomyocyte damage.39 Taurine supplementation to
rats increases expression of the myocardial taurine transporter, restor-
ing taurine movement into the myocardial cells.39 Our results contrast
with a study of healthy Golden Retrievers, which found no difference
in plasma taurine concentrations, but lower whole blood taurine con-
centrations in dogs eating non-traditional diets compared to tradi-
tional diets.8 The reasons for these contrasting findings are unclear,
but might be influenced by the other, diverse breeds included in our
study, different diets that were fed to dogs in each study, and differ-
ent diet characterizations used in each study. While the reasons that
dogs consuming GF diets had higher plasma taurine concentrations in
our study are unknown, this finding could be related to dietary inclu-
sion of taurine or methionine as an ingredient, sample handling arti-
facts, or myocardial disease and injury.
Although the number of dogs with VPCs noted on monitoring
electrocardiography during the echocardiogram was relatively low, a
greater proportion of dogs eating FDA-PLP diets had VPCs than those
eating NoFDA-PLP diets. No echocardiographic differences were
found between healthy dogs in this study eating GF and GI diets or
between healthy dogs in this study eating FDA-PLP and NoFDA-PLP
diets. In addition, no diet type differences were detected for
NT-proBNP. The lack of differences in echocardiographic measure-
ments is in contrast to a recent study in Golden Retrievers in which
FS was lower and LV diameters were larger in those eating non-
traditional diets compared to traditional diets.8 Similar to postulated
reasons for contrasting findings regarding taurine concentrations in
that publication, our study enrolled 3 breeds in addition to Golden
Retrievers and utilized different diet categorizations. The absence of
echocardiographic differences between dogs eating different diet
types in the current study could be because these dogs were clinically
healthy with a low disease prevalence, breed differences and variabil-
ity, low statistical power, or to true absence of differences. We inten-
tionally chose to study 2 breeds that are not predisposed to dilated
cardiomyopathy (Miniature Schnauzer and Whippet), 1 breed that is
predisposed to genetically-based dilated cardiomyopathy (Doberman
Pinscher), and 1 breed that appears predisposed to nDCM and taurine
TABLE 3 Differences between diet categorizations for echocardiographic variables, taurine concentrations, and cardiac biomarkers









LVIDdN (C) 1.50 (1.43-1.70) 1.62 (1.49-1.75) .11 .23 1.51 (1.42-1.73) 1.62 (1.50-1.74) .07 .99
LVIDdN (V) 1.49 (1.40-1.67) 1.59 (1.47-1.72) .11 .23 1.49 (1.39-1.70) 1.60 (1.47–1.72) .07 .99
LVIDsN (C) .95 (.85-1.05) 1.07 (.96-1.19) .02 .34 1.00 (.86-1.10) 1.07 (.96-1.19) .03 .89
LVIDsN (V) .78 (.68–.85) .85 (.74–.97) .02 .25 .81 (69–.88) .85 (.74–.97) .04 .96
FS (%) 34.0 (28.5-38.3) 28.9 (24.7-34.3) .03 .59 33.9 (26.5-38.1) 28.9 (25.0-33.7) .17 .75
LA/Ao 1.31 (1.25-1.38) 1.35 (1.25-1.45) .22 .67 1.33 (1.25-1.39) 1.35 (1.26-1.45) .28 .58
LVVd/m2 60.0 (44.3-75.0) 76.1 (55.8-95.7) .004 .19 59.8 (51.4-79.0) 76.9 (56.9-95.1) .01 .85
LVVs/m2 24.9 (15.6-31.7) 31.2 (21.5-41.2) .05 .18 24.5 (16.5-36.0) 31.4 (21.6-41.2) .03 .99
EF (%) 60.0 (55.1-64.6) 58.9 (54.0-65.0) .90 .21 60.7 (55.1-65.3) 58.5 (53.2-64.0) .43 .98
hs-cTnI (ng/mL) .076 (.028–.156) .048 (.026-.080) .001 <.001 .059 (.028–.122) .048 (.025-.085) .03 .006
NT-proBNP (pmol/L) 429 (250-653) 358 (250-586) .77 .85 414 (250-747) 357 (250-562) .63 .97
Whole blood taurine
(nmol/mL)
281 (243-316) 227 (194-278) .002 .99 268 (220-303) 228 (193-282) .05 .77
Plasma taurine (nmol/mL) 125 (101–148) 104 (86-123) <.001 .02 121 (94-142) 104 (86-121) .03 .10
Note: Median and interquartile range are shown with crude, unadjusted P values obtained from the univariable analyses and adjusted P values after
multivariable regression analysis controlling for age and breed. P < .05 after multivariable adjustment was considered to be statistically significant (bolded).
Abbreviations: EF, ejection fraction; FDA-PLP, diets with Food and Drug Administration ingredients of concern (peas, lentils, or potatoes) in the top 10
ingredients; GF, grain-free diets; GI, grain-inclusive diets; hs-cTnI, high-sensitivity cardiac troponin I; LVIDdN (C), normalized left ventricular internal
diameter in diastole by Cornell et al. formula23; LVIDdN (V), normalized left ventricular internal diameter in diastole by Visser et al formula24; LVIDsN (C),
normalized left ventricular internal diameter in systole by Cornell et al. formula23; LVIDsN (V), normalized left ventricular internal diameter in systole by
Visser et al. formula24; FS, fractional shortening; LA/Ao, left atrial to aortic ratio; LVVd/m2, left ventricular volume in diastole indexed to body surface area;
LVVs/m2, left ventricular volume in systole indexed to body surface area; NoFDA-PLP, diets without Food and Drug Administration ingredients of concern
(peas, lentils, or potatoes) in the top 10 ingredients; NT-proBNP, N-terminal pro B-type natriuretic peptide.
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deficiency (Golden Retriever). The unique differences between the
studied breeds might have reduced our ability to detect small differ-
ences between groups40,41 and our study was not planned or
powered to evaluate each breed individually. However, we consider
that the subtle, but statistically significantly higher concentrations of
hs-cTnI in these clinically healthy dogs eating GF and FDA-PLP diets
could represent subclinical cardiac injury that would not be expected
to be associated with gross echocardiographic changes. This study
could not determine whether the higher hs-cTnI in these dogs has
potential to become clinically important through eventual progression
over time to echocardiographic changes and overt cardiac disease, or
whether this finding is even clinically important for these dogs.
The correct characterization of diets that are associated with
nDCM is unknown because the cause has not yet been identified. We
chose to group diets by 2 categorizations, based on the absence or
presence of grains and based on the absence or presence of FDA-listed
ingredients of concern in the top 10 ingredients. Although these 2 cate-
gorizations are similar, there were some diets that were included in
1 categorization but not another because of specific ingredients used
and the ingredient list position. For example, some GF diets listed peas,
lentils, or potatoes after the 10th ingredient and some GI diets had
peas, lentils, or potatoes in the top 10 ingredients. It should be noted
that it is impossible to determine the exact amount of an ingredient
based on the ingredient list. Accurate description of diets of concern
remains elusive but in light of the hs-cTnI differences detected in this
study, dietary commonalities between GF and FDA-PLP diets might
prove useful for designing future studies. This study was not intended
to implicate or exonerate specific diets. The differences between the
2 ways diets were categorized, the many different diets and varieties on
the market (many of which were not fed to dogs in this study), the small
number of dogs eating specific diets in this study, and the variety of
ingredients included in different diets, limit the ability to make specific
dietary recommendations based on the results of this study. Likewise,
the diet categorizations explored in this study should not be viewed as
absolute: for example, the use of peas, lentils, or potatoes in the top 10
ingredients is observational and the cutoff at the 10th ingredient is
somewhat arbitrary; this does not mean that these ingredients below
this level are not of concern. The results of this study, however, do sup-
port the finding that diets fed to clinically healthy dogs of these 4 breeds
for at least 6 months that are GF or contain peas, lentils, or potatoes as
top 10 ingredients are associated with higher hs-cTnI concentrations
compared to diets without these characteristics.
This study has several important limitations to be considered dur-
ing interpretation and application of findings. In an attempt to limit
breed variability while evaluating several kinds of dogs, we chose to
evaluate only 4 breeds. As such, the results of this study are only
applicable to Doberman Pinschers, Golden Retrievers, Miniature
Schnauzers, and Whippets. The statistical power might have been too
low to detect differences between diet types for some variables,
especially considering the unbalanced group sizes. In addition, the
study was not designed to analyze each breed separately, and as such,
the relatively small number of dogs in each breed prevented breed-
specific analyses. Based on other published studies, we presume that
the higher hs-cTnI in dogs eating GF and FDA-PLP diets indicates
low-level cardiomyocyte injury27-30; but this hypothesis is unproven
and there could be other reasons for the observed differences. While
we screened dogs with hs-cTnI elevations from the University of Flor-
ida for some infectious diseases, we did not rule out all causes of myo-
carditis in this group of dogs. Lastly, the true prevalence of various
cardiac arrhythmias in each diet type was not evaluated in this study
because 24-hour Holter monitoring was not performed.
ACKNOWLEDGMENT
Funding provided by the American Kennel Club Canine Health Foun-
dation, grant 02661. The authors thank Melissa Pisaroglo de Carvalho,
Lana Fagman, Courtney Hanner, and Viviana Pena for technical assis-
tance, and all of the owners of the dogs who participated in this
study.
CONFLICT OF INTEREST DECLARATION
Dr Adin acknowledges research support from Nestle Purina PetCare
and is a consultant and sponsored lecturer for Ceva Animal Health
and Boehringer Ingelheim. Dr Freeman has received funding from,
given sponsored lectures for, or provided professional services to
Aratana Therapeutics, Elanco, Hill's Pet Nutrition, Nestlé Purina
PetCare, P&G Petcare (now Mars), and Royal Canin. Dr Stepien is a
consultant for Nestle Purina Petcare and has served as consultant or
sponsored lecturer for IDEXX, Ceva Animal Health, and Boehringer
Ingelheim. Dr Rush has received funding from, given sponsored lec-
tures for, or provided professional services to Aratana Therapeutics,
Elanco, Hill's Pet Nutrition, Nestlé Purina PetCare, Royal Canin, IDEXX
and Boehringer Ingelheim. Dr Tjostheim does not report conflicts of
interest. Dr. Kellihan does not report conflicts of interest. Dr Aherne
does not report conflicts of interest. Ms Vereb does not report con-
flicts of interest. Dr Goldberg does not report conflicts of interest.
The conflicts of interest reported by the authors did not influence
data collection, data interpretation, or manuscript preparation.
OFF-LABEL ANTIMICROBIAL DECLARATION
No off-label antimicrobial use.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
This study was approved by the Institutional Care and Use Commit-
tees at the University of Florida, College of Veterinary Medicine
(#201810504) and the University of Wisconsin, School of Veterinary
Medicine (#V005029-R01).
HUMAN ETHICS APPROVAL DECLARATION




John E. Rush https://orcid.org/0000-0002-8277-8996
Michael Aherne https://orcid.org/0000-0001-9599-9256
ADIN ET AL. 777
REFERENCES
1. Martin M, Johnson M, Celona B. Canine dilated cardiomyopathy: a
retrospective study of signalment, presentation and clinical findings in
369 cases. J Small Anim Pract. 2009;50:23-29.
2. Martin MWS, Stafford Johnson MJ, Strehlau G, King JN. Canine
dilated cardiomyopathy: a retrospective study of prognostic findings
in 367 clinical cases. J Small Anim Pract. 2010;51:428-436.
3. Meurs KM, Lahmers S, Keene BW, et al. A splice site mutation in a
gene encoding for PDK4, a mitochondrial protein, is associated with
the development of dilated cardiomyopathy in the Doberman
pinscher. Hum Genet. 2012;131:1319-1325.
4. Meurs KM, Friedenberg SG, Kolb J, et al. A missense variant in the
titin gene in Doberman pinscher dogs with familial dilated cardiomy-
opathy and sudden cardiac death. Hum Genet. 2019;138:515-524.
5. Simpson S, Dunning MD, Brownlie S, et al. Multiple genetic
ssociations with Irish wolfhound dilated cardiomyopathy. Biomed Res
Int. 2016;2016:1-14.
6. Adin D, DeFrancesco TC, Keene B, et al. Echocardiographic pheno-
type of canine dilated cardiomyopathy differs based on diet type.
J Vet Cardiol. 2019;21:1-9.
7. Kaplan JL, Stern J, Fascetti AJ, et al. Taurine deficiency and canine
dilated cardiomyopathy in golden retrievers fed commercial diets.
PLoS One. 2018;13:1-19.
8. Ontiveros ES, Whelchel BD, Yu J, et al. Development of plasma
and whole blood taurine reference ranges and identification of
dietary features associated with taurine deficiency and dilated cardio-
myopathy in golden retrievers: a prospective, observational
study. PLoS One. 2020;15:1-25. https://doi.org/10.1371/journal.
pone.0233206.
9. Mansilla WD, Marinangeli CPF, Ekenstedt KJ, et al. Special topic: the
association between pulse ingredients and canine dilated cardiomyop-
athy: addressing the knowledge gaps before establishing causation.
J Anim Sci. 2019;97:983-997.
10. McCauley SR, Clark SD, Quest BW, et al. Review of canine dilated
cardiomyopathy in the wake of diet-associated concerns. J Anim Sci.
2020;98:1-20.
11. Sole M, Jeejeebhoy K. Conditioned nutritional requirements and the
pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr
Metab Care. 2000;3:417-424.
12. Lourenco R, Camilo ME. Taurine: a conditionally essential amino acid
in humans? An overview in health and disease. Nutr Hosp. 2002;6:
262-270.
13. Azuma J, Sawamura A, Awata N, et al. Therapeutic effect of taurine in
congestive heart failure: a double-blind crossover trial. Clin Cardiol.
1985;8:276-282.
14. Ito T, Schaffer S, Azuma J. The effect of taurine on chronic heart fail-
ure: actions of taurine against catecholamine and angiotensin II.
Amino Acids. 2014;46:111-119.
15. Laflamme D. Development and validation of a body condition score
system for dogs. Canine Pract Nutr. 1997;22:10-15.
16. World Small Animal Veterinary Association Global Nutrition
Committee. Muscle condition score for dogs. https://wsava.org/wp-
content/uploads/2020/01/Muscle-Condition-Score-Chart-for-Dogs.
pdf. Accessed December 12, 2020.
17. Herman DS, Kavsak PA, Greene DN. Variability and error in cardiac
troponin testing: an ACLPS critical review. Am J Clin Pathol. 2017;
148:281-295.
18. Li J, Wagar EA, Meng QH. Comprehensive assessment of biotin inter-
ference in immunoassays. Clin Chim Acta. 2018;487:293-298.
19. Prantil LR, Heinze CR, Freeman LM. Comparison of carbohydrate
content between grain-containing and grain-free dry cat diets and
between reported and calculated carbohydrate values. J Feline Med
Surg. 2018;20:349-355.
20. Beloshapka AN, De Godoy MRC, Carter RA, et al. Longitudinal
changes in blood metabolites, amino acid profile, and oxidative stress
markers in american foxhounds fed a nutrient-fortified diet. J Anim
Sci. 2018;96:930-940.
21. Wess G, Domenech O, Dukes-McEwan J, Häggström J, Gordon S.
European Society of Veterinary Cardiology screening guidelines for
dilated cardiomyopathy in Doberman Pinschers. J Vet Cardiol. 2017;
19:405-415.
22. Scollan KF, Stieger-Vanegas SM, David SD. Assessment of left ven-
tricular volume and function in healthy dogs by use of one-, two-, and
three-dimensional echocardiography versus multidetector computed
tomography. Am J Vet Res. 2016;77:1211-1219.
23. Cornell CC, Kittleson MD, Torre PD, et al. Allometric scaling of M-
mode cardiac measurements in normal adult dogs. J Vet Intern Med.
2004;18:311-321.
24. Visser LC, Ciccozzi MM, Sintov DJ, Sharpe AN. Echocardiographic
quantitation of left heart size and function in 122 healthy dogs: a pro-
spective study proposing reference intervals and assessing repeatabil-
ity. J Vet Intern Med. 2019;33:1909-1920.
25. Rishniw M, Erb H. Evaluation of four 2-dimensional echocardio-
graphic methods of assessing left atrial size in dogs. J Vet Intern Med.
2000;14:429-435.
26. Winter RL, Saunders AB, Gordon SG, et al. Analytical validation and
clinical evaluation of a commercially available high-sensitivity immu-
noassay for the measurement of troponin i in humans for use in dogs.
J Vet Cardiol. 2014;16:81-89.
27. Langhorn R, Willesen JL. Cardiac troponins in dogs and cats. J Vet
Intern Med. 2016;30:36-50.
28. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in
coronary vs. non-coronary disease. Eur Heart J. 2011;32:404-411.
29. Kovell LC, Yeung EH, Miller ER, et al. Healthy diet reduces markers of
cardiac injury and inflammation regardless of macronutrients: results
from the OmniHeart trial. Int J Cardiol. 2020;299:282-288. https://
doi.org/10.1016/j.ijcard.2019.07.102.
30. Jones M, O'Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-
sensitive cardiac troponin-I facilitates timely detection of subclinical
anthracycline-mediated cardiac injury. Ann Clin Biochem. 2017;54:
149-157.
31. Gresslien T, Agewall S. Troponin and exercise. Int J Cardiol. 2016;221:
609-621. https://doi.org/10.1016/j.ijcard.2016.06.243.
32. Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K,
Elliott J. The combined prognostic potential of serum high-sensitivity
cardiac troponin I and N-terminal pro-B-type natriuretic peptide con-
centrations in dogs with degenerative mitral valve disease. J Vet
Intern Med. 2012;26:302-311.
33. Hazzaa SM, El-Roghy ES, Abd Eldaim MA, et al. Monosodium gluta-
mate induces cardiac toxicity via oxidative stress, fibrosis, and P53
proapoptotic protein expression in rats. Environ Sci Pollut Res. 2020;
27:20014-20024.
34. Heinze CR, Larsen JA, Kass PH, et al. Plasma amino acid and whole
blood taurine concentrations in cats eating commercially prepared
diets. Am J Vet Res. 2009;70:1374-1382.
35. Trautwein EA, Hayes KC. Plasma and whole blood taurine concentra-
tions respond differently to taurine supplementation (humans) and
depletion (cats). Z Ernahrungswiss. 1995;34:137-142.
36. Schuller-Levis G, Park E. Is taurine a biomarker? Adv Clin Chem. 2006;
41:1-21.
37. Lombardini J, Cooper M. Elevated blood taurine levels in acute and
evolving myocardial infarction. J Lab Clin Med. 1981;98:849-859.
38. Bhatnagar SK, Welty JD, al Yusuf AR. Significance of blood taurine
levels in patients with first time acute ischaemic cardiac pain. Int J
Cardiol. 1990;27:361-366.
39. Shi YR, Bu DF, Qi YF, et al. Dysfunction of myocardial taurine trans-
port and effect of taurine supplement in rats with isoproterenol-
induced myocardial injury. Acta Pharmacol Sin. 2002;23:910-917.
40. Seckerdieck M, Holler P, Smets P, Wess G. Simpson's method of discs
in Salukis and Whippets: echocardiographic reference intervals for
778 ADIN ET AL.
end-diastolic and end-systolic left ventricular volumes. J Vet Cardiol.
2015;17:271-281. https://doi.org/10.1016/j.jvc.2015.08.002.
41. Bavegems V, Duchateau L, Sys SU, et al. Echocardiographic reference
values in whippets. Vet Radiol Ultrasound. 2007;48:230-238.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Adin D, Freeman L, Stepien R, et al.
Effect of type of diet on blood and plasma taurine
concentrations, cardiac biomarkers, and echocardiograms in 4
dog breeds. J Vet Intern Med. 2021;35:771–779. https://doi.
org/10.1111/jvim.16075
ADIN ET AL. 779
